Research programme: obesity therapy - Ambrx

Drug Profile

Research programme: obesity therapy - Ambrx

Alternative Names: ARX-328

Latest Information Update: 09 Jan 2014

Price : $50

At a glance

  • Originator Ambrx
  • Class Adipokines
  • Mechanism of Action Leptin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 09 Jan 2014 Preclinical development is ongoing in USA
  • 08 Jul 2011 Preclinical trials in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top